Best Practice & Research Clinical Rheumatology
Volume 23, Issue 5 , Pages 599-608 , October 2009

Using biology of disease to understand and guide therapy of JIA

  • Berent J. Prakken, MD, PhD (Professor)

      Affiliations

    • Department of Pediatric Immunology/Rheumatology, University Medical Centre Utrecht, Wilhelmina Children's Hospital, Lundlaan 6/Postbus 85090, 3584 EA/3508 AB Utrecht, The Netherlands
    • Eureka Institute for Translational Medicine, EU, USA
    • ,
  • Salvatore Albani, MD, PhD (The Charles and Suzanne Stephens Chair of Rheumatology Research, Professor of Medicine and Pediatrics, and Director Arizona Arthritis Center)

      Affiliations

    • Arizona Arthritis Center, University of Arizona, 1501 N. Campbell Avenue, PO Box 245093, Tucson, AZ 85724-5093, USA
    • Eureka Institute for Translational Medicine, EU, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 520 626 7902; Fax +1 520 626 5018.

References 

  1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392
  2. Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet. 1998;351:969–973
  3. Thomson W, Donn R. Juvenile idiopathic arthritis genetics–What's new? What's next?. Arthritis Res. 2002;4:302–306
  4. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:1384–1387
  5. Gonzalez B, Larrañaga C, León O, et al. Parvovirus B19 may have a role in the pathogenesis of juvenile idiopathic arthritis. J Rheumatol. 2007;34:1336–1340
  6. Pancewicz S, Popko J, Rutkowski R, et al. Activity of lysosomal exoglycosidases in serum and synovial fluid in patients with chronic Lyme and rheumatoid arthritis. Scand J Infect Dis. 2009;9:1–6
  7. Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA, et al. Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:639–646
  8. Massa M, Mazzoli F, Pignatti P, et al. Proinflammatory responses to self-HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:2721–2729
  9. Bywaters EG. Pathologic aspects of juvenile chronic polyarthritis. Arthritis Rheum. 1977;20:271–276
  10. Wynne-Roberts CR, Anderson CH, Turano AM, Baron M. Light- and electron microscopic findings of juvenile rheumatoid arthritis synovium: comparison with normal juvenile synovium. Semin Arthritis Rheum. 1978;7:287–302
  11. Silvermann ED, Isacovics B, Petsche D, Laxer D. Synovial fluid cells in juvenile arthritis: evidence of selective T cell migration to inflamed tissue. Clin Exp Immunol. 1993;91:90–95
  12. Black AP, Bhayani H, Ryder CA, et al. T-cell activation without proliferation in juvenile idiopathic arthritis. Arthritis Res. 2002;4:177–183
  13. Murray K, Thompson SD, Glass DN. Pathogenesis of juvenile chronic arthritis: genetic and environmental factors. Arch Dis Child. 1997;77:530–534
  14. Moroldo MB, Donnelly P, Saunders J, et al. Transmission disequilibrium as a test of linkage and association between HLA alleles and pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 1998;41:1620–1624
  15. Prahalad S, Ryan MH, Shear ES, et al. Juvenile rheumatoid arthritis: linkage to HLA demonstrated by allele sharing in affected sibpairs. Arthritis Rheum. 2000;43:2335–2338
  16. Wedderburn LR, Patel A, Varsani H, Woo P. Divergence in the degree of clonal expansions in inflammatory T cell subpopulations mirrors HLA-associated risk alleles in genetically and clinically distinct subtypes of childhood arthritis. Int Immunol. 2001;13:1541–1550
  17. Nistala K, Moncrieffe H, Newton KR, et al. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 2008;58:875–887
  18. Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J Clin Invest. 1994;94:25–33
  19. Fischer DC, Kolbe-Busch S, Stocker G, et al. Development of enzyme immunoassays specific for keratan sulphate- and core-protein-epitopes of the large aggregating proteoglycan from human articular cartilage. Eur J Clin Chem Clin Biochem. 1994;32:285–291
  20. Guerassimov A, Zhang Y, Banerjee S, et al. Cellular immunity to the G1 domain of cartilage proteoglycan aggrecan is enhanced in patients with rheumatoid arthritis but only after removal of keratan sulfate. Arthritis Rheum. 1998;41:1019–1025
  21. Zou J, Zhang Y, Thiel A, et al. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford). 2003;42:846–855
  22. Zou J, Appel H, Rudwaleit M, et al. Analysis of the CD8 + T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Ann Rheum Dis. 2005;64:722–729
  23. Kamphuis S, Hrafnkelsdóttir K, Klein MR, et al. Novel self-epitopes derived from aggrecan, fibrillin, and matrix metalloproteinase-3 drive distinct autoreactive T-cell responses in juvenile idiopathic arthritis and in health. Arthritis Res Ther. 2006;8:R178
  24. Waggett AD, Kielty CM, Shuttleworth CA. Microfibrillar elements in the synovial joint: presence of type VI collagen and fibrillin-containing microfibrils. Ann Rheum Dis. 1993;52:449–453
  25. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004;4:617–629
  26. Gattorno M, Gerloni V, Morando A, et al. Synovial membrane expression of matrix metalloproteinases and tissue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol. 2002;29:1774–1779
  27. ter Steege J, Vianen M, van Bilsen J , et al. Identification of self-epitopes recognized by T cells in rheumatoid arthritis demonstrates matrix metalloproteinases as a novel T cell target. J Rheumatol. 2003;30:1147–1156
  28. Van Bilsen JH, Wagenaar-Hilbers JP, Grosfeld-Stulemeijer MC, et al. Matrix metalloproteinases as targets for the immune system during experimental arthritis. J Immunol. 2004;172:5063–5068
  29. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–562
  30. de Kleer IM, Wedderburn LR, Taams LS, et al. CD4 + CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol. 2004;172:6435–6443
  31. Ruprecht CR, Gattorno M, Ferlito F, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med. 2005;201:1793–1803
  32. Prakken B, Kuis W, van Eden W, Albani S. Heat shock proteins in juvenile idiopathic arthritis: keys for understanding remitting arthritis and candidate antigens for immune therapy. Curr Rheumatol Rep. 2002;4:466–473
  33. Kamphuis S, Kuis W, de Jager W, et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet. 2005;366:50–56
  34. Lee L, Buckley C, Blades MC, et al. Identification of synovium-specific homing peptides by in vivo phage display selection. Arthritis Rheum. 2002;46:2109–2120
  35. Prakken BJ, Samodal R, Le TD, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2004;101:4228–4233
  36. Roncarolo MG, Bacchetta R, Bordignon C, et al. Type 1 T regulatory cells. Immunol Rev. 2001;182:68–79
  37. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10:801–805
  38. Von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005;6:338–344
  39. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol. 2005;6:353–360
  40. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptide. Immunity. 1994;1:751–761
  41. Schett G, Tohidast-Akrad M, Steiner G, Smolen J. The stressed synovium. Arthritis Res. 2001;3:80–86
  42. Gattorno M, Prigione I, Vignola S, et al. Levels of soluble CD27 in sera and synovial fluid and its expression on memory T cells in patients with juvenile idiopathic arthritides. Clin Exp Rheumatol. 2002;20:863–866
  43. Murray KJ, Grom AA, Thompson SD, et al. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol. 1998;25:1388–1398
  44. Coutinho A, Hori S, Carvalho T, et al. Regulatory T cells: the physiology of autoreactivity in dominant tolerance and quality control of immune responses. Immunol Rev. 2001;182:89–98
  45. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295–302
  46. Maloy KJ, Salaun L, Cahill R, et al. CD4+CD25+ T cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med. 2003;197:111–119
  47. Murphy TJ, Choileain NN, Zang Y, et al. CD4+CD25+ regulatory T cells control innate immune reactivity after injury. J Immunol. 2005;174:2957–2963
  48. Massa M, Passalia M, Manzoni S, et al. Differential Recognition of Heat-Shock Protein DnaJ-Derived Epitopes by Effector and Treg Cells Leads to Modulation of Inflammation in Juvenile Idiopathic Arthritis. Arthritis Rheum. 2007;56:1648–1657
  49. Fisson S, Djelti F, Trenado A, et al. Therapeutic potential of self-antigen-specific CD4 + CD25+ regulatory T cells selected in vitro from a polyclonal repertoire. Eur J Immunol. 2006;36:817–827
  50. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–R1288
  51. De Benedetti F, Meazza C, Vivarelli M, et al., British Paediatric Rheumatology Study Group  Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2003;48:1398–1407
  52. de Jager W, Hoppenreijs EP, Wulffraat NM, et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2007;66:589–598Erratum in: Ann Rheum Dis 2008; 67: 280
  53. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. 2007;81:28–37
  54. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13:1042–1049
  55. Foell D, Ichida F, Vogl T, et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet. 2003;361:1270–1272
  56. Albani S. Infection and molecular mimicry in autoimmune diseases of childhood. Clin Exp Rheumatol. 1994;12:S35–S41
  57. Prakken BJ, van der Zee R, Anderton SM, et al. Tolerance to an arthritogenic T-cell epitope of HSP65 and the regulation of experimental arthritis. Ann N Y Acad Sci. 1996;778:425–426
  58. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with heat-shock protein peptide (DiaPep277): a randomized, double-blind, phase II trial. Lancet. 2002;358:1749–1753
  59. Anderton SM, Wraith DC. Selection and fine-tuning of the autoimmune T-cell repertoire. Nat Rev Immunol. 2002;2:487–498
  60. De Kleer IM, Kamphuis SM, Rijkers GT, et al. The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30 T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. Arthritis Rheum. 2003;48:2001–2010

PII: S1521-6942(09)00074-6

doi: 10.1016/j.berh.2009.07.003

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 5 , Pages 599-608 , October 2009

Article Tools